



Universiteit
Leiden
The Netherlands

Time is of the essence - investigating kinetic interactions between drug, endogenous neuropeptides and receptor

Nederpelt, I.

Citation

Nederpelt, I. (2017, April 6). *Time is of the essence - investigating kinetic interactions between drug, endogenous neuropeptides and receptor*. Retrieved from <https://hdl.handle.net/1887/47526>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/47526>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/47526> holds various files of this Leiden University dissertation.

Author: Nederpelt, I.

Title: Time is of the essence - investigating kinetic interactions between drug, endogenous neuropeptides and receptor

Issue Date: 2017-04-06

Chapter 2

Kinetic profile of neuropeptide – receptor interactions

Indira Nederpelt

Julia Bunnik

Adriaan P. IJzerman

Laura H. Heitman

Adapted from *Trends in Neurosciences* **2016** 39 (12): 830–839

Abstract

Currently, drug discovery focusses only on quantifying pharmacological parameters, sometimes including binding kinetics, of drug candidates. For a complete understanding of a drug's desired binding kinetics, the kinetics of both the target and its endogenous ligands should be considered. This is because the release and binding kinetics of endogenous ligands in addition to receptor internalization rates are significant contributors to drug-target interactions.

Here, we discuss the kinetic profile of three neuropeptides and their receptors; gonadotropin-releasing hormone receptor (GnRHR), neuropeptide Y receptors, and corticotropin-releasing factor receptor 1 (CRF₁R). These three examples provide new insights into the importance of kinetic profiles which could improve the understanding of desired drug-target binding kinetics and advance drug discovery for various neurological and psychiatric illnesses.

Background of neuropeptides in drug discovery

Over the past 40 years, many neuropeptides have been identified in the central nervous system (CNS) and the peripheral nervous system (PNS). Neuropeptides are 3-100 amino acid long polypeptides and are synthesized by neurons. Neuropeptides act on either neural substrates, such as neurons and glial cells or on non-neuronal target cells [1]; they mediate neuronal communication by acting on neuropeptide receptors. Neuropeptide receptors include over 44 receptor families, of which most are G protein-coupled receptors (GPCRs). Neuropeptides and their cognate receptors are involved in many physiological and behavioral functions, such as pain regulation, blood pressure, body temperature, feeding behavior, reproduction, sleep, and learning and memory [2]. Therefore, neuropeptide transmission is an attractive area for drug discovery in several therapeutic areas, including inflammatory conditions [3], epilepsy [4] and psychiatric diseases [5]. Release of endogenous neuropeptides is often pulsatile or in bursts in response to stress, resulting in instant high local concentrations which adds complexity to the development of drugs targeting neuropeptide receptors [6].

Optimized ligand-receptor binding kinetics is an emerging concept in drug discovery research

Many drug candidates have failed in clinical trials, over 50% due to a reported lack of efficacy [7]. Several studies suggest that binding kinetics, particularly the lifetime of the ligand-receptor binary complex, may be more relevant for *in vivo* drug efficacy than their typical equilibrium parameters obtained *in vitro*, such as target affinity (K_i) and potency (IC_{50}) [8-10]. This lifetime can be expressed as the drug-target residence time (RT) and is reflected by the dissociation rate constant (k_{off}) of the ligand or drug. The k_{off} value can simply be converted to RT, which is equal to the reciprocal of k_{off} ($RT = 1/k_{off}$).

Currently, several successfully marketed drugs in the GPCR field have been proven in retrospect to have long RT [11]. These drugs illustrate the benefits of optimized binding kinetics in drug discovery represented by lower dosages, increased efficacy and/or safety. For example, the NK1 receptor antagonist aprepitant has superior *in vivo* efficacy in comparison to other NK1 receptor antagonists due to its slow receptor dissociation [11]. As another example, patients with asthma or chronic obstructive pulmonary disease (COPD) can benefit from the slowly dissociating β_2 -adrenoreceptor agonist olodaterol [12]. The bronchodilating effects of this drug last up to 24 h. which allows for once-daily administration. However, it is important to note that slow dissociation rates are not always desired. Long RT can also lead to adverse effects and thereby decrease drug safety in the patient [10]. An example of a successful drug with a short residence time is quetiapine, a dopamine D_2

receptor antagonist approved for the treatment of schizophrenia and bipolar disorder. This antipsychotic drug was shown to have fewer (on-target) side effects than other dopamine D₂ receptor antagonists on the market [13]. Altogether, incorporating optimized binding kinetics prospectively could improve the success rate in drug discovery and development and thus of drugs entering the market.




Figure 1. Schematic representation of the structure of this review. Drugs are often competing with endogenous ligands but the kinetic profile of the target receptor and its endogenous ligand(s) are often overlooked. In this review the endogenous ligand release kinetics, endogenous ligand binding kinetics and receptor fate (e.g., internalization kinetics and degradation pathways), i.e. kinetic profiles, of three exemplary and diverse neuropeptide receptor classes and their endogenous ligands will be discussed.

The kinetic profile of a target receptor and its endogenous ligand

The majority of successful drugs achieve their effect by competing with endogenous ligands for the same binding site. Therefore, understanding the pharmacological and physiological behavior of endogenous ligands in the human body is crucial. In contrast to the *in vitro* test tube situation, the human body is an open system. Consequently, the concentration of endogenous ligand, drug and target receptor change over time as these molecules enter and leave the system [10, 14]. Moreover, in order to comprehend desired drug-target kinetics, awareness of the kinetic profile of the target receptor and its endogenous ligand(s) is essential. Firstly, it is imperative to consider the time scale and rate of endogenous ligand release as this can result in temporarily high local concentrations. Secondly, knowledge of the rates of association to and dissociation from the receptor not only of the drug candidate but also of the endogenous ligand should be considered as these parameters can be a limitation to the availability of the unoccupied receptor. Finally, to get a better understanding of the *in vivo* effects of a drug candidate, insight into the rate at which receptors desensitize or internalize under normal and pathophysiological conditions is necessary [15]. Agonist responses are usually regulated by receptor desensitization and internalization and this can limit the effect and duration of receptor signaling [16]. Moreover, receptor complexation with receptor activity-modifying proteins (RAMPs) [17], as well as receptor ubiquitination and other degradation steps are of influence on receptor half-life [18] and although literature on this topic is sparse more knowledge could aid drug discovery [19]. Accordingly, the impact of a long RT drug may be diminished when receptors are rapidly degraded or recycled [15, 20]. Attempts to simultaneously address these aspects in mathematical models that allow such an *in vitro/in vivo* translation are encouraging. These models can be of great value to analyze experimental data and simulate various cases of drug treatment in a comprehensive and integrative fashion [21].

In brief, to improve drug discovery more insight towards the kinetic characteristics of both drug and the endogenous ligand and its target, i.e. the full kinetic profile, is crucial (Figure 1). We propose a new perspective to drug discovery, where increased attention is paid to 1) release frequency of endogenous ligands (Box 1, Box 2 and Figure 2), 2) binding kinetics of endogenous ligands, and 3) internalization and degradation rates of target receptors. To demonstrate the diversity in kinetic profiles of neuropeptide receptors, we provide a synthesis of the kinetic profiles of three exemplary and diverse neuropeptide receptors and their endogenous ligands, i.e. gonadotropin-releasing hormone receptor (GnRHR), neuropeptide Y receptors, and corticotropin-releasing factor receptor 1 (CRF₁R) (Figure 1).




Figure 2. Schematic representation of biosynthesis, release and degradation kinetics ('endogenous ligand kinetics') of endogenous neuropeptides GnRH (A), NPY (B) and CRF (C) in the human body at physiological conditions. This cartoon describes the location of synthesis of the neuropeptide, followed by release, transport, and binding at its cognate receptor. Finally, the endogenous neuropeptide is degraded by endopeptidases. Sources of medical illustrations: Somersault1824 Library of Science & Medical Illustrations [22] and Servier medical art. [23].

Kinetic profile of neuropeptide receptors and their endogenous ligands

GnRH and the GnRHR

Gonadotropin-releasing hormone (GnRH) is a neuropeptide that mediates the central control of the reproductive system and is released by the hypothalamus. GnRH activates GnRH receptors (GnRHRs) in the anterior pituitary and subsequently stimulates secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). GnRH is released in high and low frequency pulses dependent on gender and reproductive cycles (Box 1 and Figure 2) [24], and plasma concentrations range from 0.1-2.0 pg/ml (i.e. 84.5 nM – 1.7 μ M) [25]. GnRHR belongs to the class A rhodopsin-like family of GPCRs and GnRHR is predominantly coupled to $G_{\alpha_{q/11}}$ proteins. A unique feature of the GnRHR is that it, unlike all other GPCRs, lacks an intracellular C-terminal tail [26]. GnRHR is successfully targeted to treat hormone-dependent diseases such as prostate cancer [27] with either antagonists or agonists that act as functional antagonist.

In 1979 a study demonstrated that radiolabeled GnRH (i.e., 125 I-GnRH) associated rapidly to ovine anterior pituitary homogenates with a k_{on} value of 0.78 nM⁻¹ min⁻¹.

Dissociation of the agonist was extremely rapid, with a k_{off} value of 0.18 min^{-1} , translating into a RT of 5.6 min which was calculated from the initial slope of the dissociation curve [28].

More recently [29], two novel competition association assays were developed that allowed for the first time the determination of kinetic receptor binding characteristics of a series of peptide agonists for the human GnRH receptor, including its endogenous ligand GnRH. Firstly, a novel radioligand binding competition association assay was developed in

Box 1: Biosynthesis, release and degradation of endogenous neuropeptides

Neuropeptides are generally synthesized from larger precursors in the neuronal cell body upon stress stimuli [6]. The precursors are stored in vesicles, where they are degraded by convertases into active peptides. Neuropeptides are transported to the release sites at neurons and released by exocytosis, where they bind their cognate receptor [30]. The kinetics of neuropeptide synthesis, release and degradation is presented in Figure 2.

Gonadotropin-releasing hormone

- GnRH is synthesized in the hypothalamus from a precursor polypeptide by enzymatic processing [31-33].
- GnRH is released in pulses from the hypothalamus. GnRH secretion is regulated both by the feedback actions of gonadal steroids and neural input from higher cognitive and sensory centers [33]. The pattern of pulsatile GnRH secretion ranges from minutes to hours and varies between sexes, during reproductive life and during the menstrual cycle in females [24] and ranges in frequency between 30 min and 3-4 hours [34].
- GnRH is rapidly hydrolyzed (half-life 2-4 min) into GnRH 1-5 by thimet oligopeptidase (EC 3.4.24.15) both in the hypothalamus and the anterior pituitary [35-37].

Neuropeptide Y

- NPY is synthesized in the hypothalamus and in the peripheral nervous system by sympathetic neurons [38]
- NPY is released in high frequency bursts (every 5 min) from sympathetic nerve terminals, upon stress stimuli or pathological conditions [39, 40].
- NPY is rapidly hydrolysed (half-life approximately 12 min) by peptidases, including dipeptidyl peptidase IV (EC 3.4.14.5) and aminopeptidase P (EC 3.4.11.9) [41, 42].

Corticotropin-releasing factor and Urocortin I

- CRF and UcnI are synthesized and released by the paraventricular nucleus of the hypothalamus [43].
- The axons of hypothalamic neurons release CRF and UcnI (approximately every 5 min) into the hypophyseal portal blood in reaction to stress [6].
- CRF and UcnI are rapidly hydrolyzed (half-life 12-73 min) by endothelin-converting enzyme 1 (ECE1, EC 3.4.24.71) in the brain [44, 45].

which GnRH had k_{on} , k_{off} and RT values of $0.06 \pm 0.01 \text{ nM}^{-1} \text{ min}^{-1}$, $0.2 \pm 0.02 \text{ min}^{-1}$, and $6.3 \pm 0.6 \text{ min}$ at room temperature, respectively (Table 1).

Secondly, a homogenous time-resolved fluorescence (TR-FRET) Tag-lite™ method was developed as an alternative assay for the same purpose. These TR-FRET experiments provided similar k_{on} , k_{off} and RT values for GnRH of $0.02 \pm 0.01 \text{ nM}^{-1} \text{ min}^{-1}$, $0.44 \pm 0.3 \text{ min}^{-1}$, and $2.3 \pm 1.6 \text{ min}$ at room temperature, respectively [29] (Table 1).

Table 1. Qualitative overview of the kinetic profile, i.e. the release kinetics of the endogenous ligand(s), binding kinetics and receptor internalization rates, of the GnRH receptor, NPY receptors and CRF1 receptor (see also Box 1).

Neuropeptide system		Fast*	Medium*	Slow*
GnRH	Release kinetics**	GnRH	X	X
	Binding kinetics	GnRH-GnRHR	X	
	Internalization kinetics	GnRHR		X
NPY	Release kinetics***	NPY	X	
	Binding kinetics	NPY-Y ₁ R	k _{on}	k _{off}
		NPY-Y ₂ R	k _{on}	k _{off}
		NPY-Y ₅ R	k _{on}	k _{off}
	Internalization kinetics	Y ₁ R	X	
		Y ₂ R		X
		Y ₅ R		X
CRF	Release kinetics***	CRF	X	
		UCNI	X	X
	Binding kinetics	CRF-CRF ₁ R	k _{on}	k _{off}
		UCNI-CRF ₁ R		X
	Internalization kinetics	CRF ₁ R	males	females

* Fast, medium and slow kinetics are an arbitrary categorization in proportion to the target system, exact rates can be found in the corresponding paragraph.

** GnRH release is pulsatile ranging from minutes to hours and depends on gender, age and menstrual cycle, see also Box 1.

*** NPY, CRF and UCNI are released in high frequency bursts in response to stress or pathological conditions, see also Box 1.

The lack of an intracellular C-terminal tail on the GnRH receptor results in the absence of rapid arrestin-mediated desensitization and in very slow internalization rates [26, 46]. Madziva *et al.* showed less than 50% internalization after 60 min stimulation with a GnRH analogue [47]. Additionally, Pawson *et al.* showed that mammalian GnRHRs (human

and rat) undergo slow, constitutive (i.e. agonist-independent) internalization [46]. The importance of a C-terminal tail for receptor internalization was shown by two studies; firstly, the catfish GnRH receptor that does possess an intracellular C-terminal tail displayed rapid desensitization and internalization. It was shown that approximately 50% of the catfish GnRH receptors were internalized after 15 min stimulation with chicken II GnRH (endocytosis rate constant = 0.099 min^{-1}) [48]. Secondly, addition of a functional intracellular C-terminal tail of the thyrotropin-releasing hormone receptor (TRHR) to the rat GnRHR produced rapid desensitization and increased receptor internalization rates [48].

In brief, drugs targeting the GnRHR are competing with fast association and dissociation kinetics of endogenous GnRH that is released in pulses ranging from minutes to hours reaching plasma concentrations up to $1.7 \text{ }\mu\text{M}$. In particular, high frequency GnRH bursts should be considered when designing drugs competing with GnRH. In addition, the GnRHR internalizes slowly and is thus not a limiting factor for drugs to be effective. We hypothesize that (functional) antagonists targeting the GnRH receptor should have a long residence time to overcome the high frequency pulses and fast association kinetics of the endogenous ligand. This is particularly beneficial when chronic treatment is desired, e.g. for treatment of prostate cancer or endometriosis.

Box 2: Alternative mechanisms involved in regulating ligand concentrations

Neuropeptides are generally degraded by peptidases, and reuptake systems or binding proteins are often not involved in regulating free ligand concentrations. However, a few exceptions have been reported where alternative mechanisms are proposed to regulate high neuropeptide concentrations.

For instance, a binding protein has been discovered, called the CRF binding protein (CRF-BP), that binds CRF, Ucn1 and their associated peptides with high affinity [49]. This protein is broadly distributed throughout the brain and its predominant role is to bind and clear CRF from the blood. CRF-BP is also expressed in the liver and placenta where it is believed to modulate CRF levels and protect the body from increased plasma CRF levels, particularly during late stages of pregnancy [50].

Another exception is reported for cholecystokinin octapeptide (CCK8). The degradation of CCK8 by peptidases is much slower in comparison to other neuropeptides and therefore an alternative control mechanism was hypothesized. A highly selective uptake mechanism was reported that together with peptidases enables termination of CCK8 activity [51].

Taken together, ligand-binding proteins and reuptake systems, although rare, can play a role in regulating free neuropeptide concentrations and should therefore be considered regarding endogenous neuropeptide concentrations.

Neuropeptide Y and Neuropeptide Y receptors

Neuropeptide Y (NPY) is a 36 amino acid neuropeptide hormone that acts as a neurotransmitter in the central nervous system (CNS). NPY is the principal endogenous agonist at neuropeptide Y type 1 (Y₁), type 2 (Y₂) and type 5 (Y₅) receptors. NPY is released in high frequency bursts upon stress stimuli (Box 1 and Figure 2) [39] and plasma concentrations are reported to be around 10 µM [52]. NPY receptors belong to class A GPCRs and are coupled to G_i or G_o proteins [53]. NPY receptors and their endogenous ligands are involved in the control of appetite, inhibition of anxiety in the CNS, presynaptic inhibition of neurotransmitter release in the CNS and periphery, the modulation of circadian rhythm and pain transmission [54]. NPY receptors are mainly targeted to treat stress-related disorders but also in pain treatment, cancer and epilepsy [2].

The kinetic binding profile of endogenous neuropeptide Y ligands to human Y₁, Y₂, and mouse Y₅ receptors was extensively studied by Dautzenberg *et al.* At 22°C, ¹²⁵I-NPY displays rapid association to hY₁, hY₂ and mY₅ receptors (Table 1). Dissociation of ¹²⁵I-NPY from the mY₅ receptor and hY₁ receptor provided residence times between 50 and 80 min. In contrast, minimal dissociation (approximately 20%) of ¹²⁵I-NPY from both recombinant and endogenous Y₂ receptor was observed after 24 h incubation. These findings indicate a pseudo-irreversible binding mode of NPY to the hY₂ receptor [55], which adds complexity to drug development targeting the hY₂ receptor.

Receptor internalization rates, as well as subsequent degradation or resensitization differ substantially between the different NPY receptor subtypes. Upon human NPY exposure, the Y₁ receptor is rapidly internalized via clathrin-dependent endocytosis [56-58]. In addition, resensitization studies demonstrated that the Y₁ receptor is rapidly recycled back to the cell membrane [56, 58, 59]. In contrast, Y₂ receptors neither internalize nor desensitize [56], or only to a small extent with extremely slow internalization rates after prolonged agonist exposure [57, 60]. Internalization of Y₅ receptors has not been extensively studied yet. However, it was reported that this receptor internalizes to a much slower extent than Y₁ [60-62].

In conclusion, target kinetics for the NPY receptor subtypes vary greatly and NPY is released in high frequency bursts upon stress stimuli with plasma concentrations around 10 µM. Rapid association and dissociation kinetics as well as internalization rates were observed for the NPY-hY₁ receptor complex. In contrast, while the binding kinetics of NPY to the hY₂ receptor are similar to the hY₁ receptor, internalization of hY₂ is extremely slow. hY₅ internalization has also been reported to be slow, with fast association and slow dissociation rates of NPY. Therefore, we postulate that drugs with fast binding kinetics are desirable when targeting the hY₁ receptor, while fast association and slow dissociation kinetics are beneficial for hY₂ and hY₅ receptors. Slowly dissociating agonists are particularly interesting

for cancer treatment as they might accelerate receptor internalization [63] while a slowly dissociating antagonist could be beneficial for the treatment of obesity [64].

CRF, UcnI and the CRF₁R

Corticotropin releasing factor (CRF) and urocortin 1 (UcnI) are hormones that are the primary CNS neuromodulators of the hypothalamic-pituitary-adrenal axis. CRF and UcnI regulate adrenocorticotrophic hormone (ACTH) secretion by the pituitary and are critical neurotransmitters in the neuroendocrine and behavioral response to stress [67]. CRF and UcnI are released in high frequency bursts in response to stress (Box 1 and Figure 2) [6]. UcnI is mainly expressed in cell bodies of the Edinger Westphal nucleus in the brain while CRF is more widely expressed in the CNS [68]. Plasma concentrations of UcnI are reported to reach up to 5 μ M, while maximal CRF concentrations are much lower (around 2 pM). During stress and/or pathological conditions levels of both endogenous ligands increase, which is most noticeable for CRF of which levels can go up to 0.5 mM [69-71]. CRF and UcnI exert their effect by activation of two CRF receptor subtypes, CRF₁ and CRF₂ receptors. These receptors both belong to the secretin-like class B subfamily of GPCRs and are primarily coupled to G_s proteins. Several studies have indicated the involvement of the CRF system in human stress disorders, such as anxiety, depression and addiction [72].

Ligand binding kinetics studies of CRF and UcnI to the CRF₁ receptor are limited (Table 1). In an

Box 3: Examples of drugs targeting neuropeptide GPCRs with optimized binding kinetics.

As this was all studied in retrospect, these examples demonstrate the need for a better understanding of the kinetic profile of the target receptor and its endogenous ligands, in addition to the drug candidate.

Candesartan is a marketed angiotensin II subtype-1 (AT₁) receptor antagonists for the treatment of hypertension. It has a residence time of 173 min (37°C) [11].

Aprepitant and **netupitant** are marketed NK₁R antagonists to treat chemotherapy-induced emesis. Aprepitant has a residence time of 154 min (22°C) [11] and netupitant has been reported as an insurmountable antagonist with antagonistic effects lasting over 5 hours [65].

Suvorexant is a dual orexin receptor antagonist to treat insomnia. It has a residence time of 83 min for the orexin type 2 (OX₂) receptor (room temperature) [66].

Buserelin is a GnRH peptide agonist used to treat hormone dependent diseases. It has a reported residence time of 111 min at 25 °C [29].

early study De Souza *et al.*, studied the binding of ¹²⁵I-[Tyr⁰] CRF (¹²⁵I-rCRF) to rat olfactory membranes at different temperatures [73]. This study demonstrated temperature-dependent ¹²⁵I-rCRF association to rat CRF₁ receptors with a k_{on} value of 0.52 nM⁻¹ min⁻¹ at 23°C. At this temperature, dissociation was reversible and monophasic, with a k_{off} value of 0.007 min⁻¹ and

RT of 143 min while association and dissociation were more rapid at physiological temperature [73]. In contrast, [³H]-UcnI association to the human CRF₁ receptor was slow and monophasic with a k_{on} value of $0.06 \pm 0.024 \text{ nM}^{-1} \text{ min}^{-1}$ while dissociation was faster in comparison to CRF with a reported k_{off} value of $0.017 \pm 0.007 \text{ min}^{-1}$ and RT of 58 min at room temperature [74].

CRF₁ receptors undergo rapid desensitization and internalization during continuous exposure to CRF or UcnI [75]. Although UcnI- and CRF-induced CRF₁ receptor internalization occurred to a similar degree, the receptor was shown to recycle and resensitize more efficiently after CRF stimulation [44]. Moreover, there is evidence of sex differences in CRF₁ receptor signaling and trafficking [76]. In male rats, a swim stress paradigm promoted CRF₁ receptor β -arrestin2 association, and internalization in LC neurons. However, in female rats stress-induced CRF₁ receptor- β -arrestin 2 association remained low, and stress-induced CRF₁ receptor internalization was impaired [76]. Valentino *et al.* suggested that sex biases in both CRF₁ receptor coupling to G proteins, and CRF₁- β -arrestin 2 association makes females more sensitive to acute stress and less able to adapt to chronic stress [77].

To summarize, although ligand binding kinetics studies on the CRF₁ receptor are limited, it is likely that drugs targeting the CRF₁ receptor are competing with fast binding kinetics of CRF but slower binding kinetics of UcnI. Additionally, CRF₁ receptor desensitization and internalization is fast in males but slow in females. These gender-specific internalization kinetics should be taken into account in the design of novel agonistic drugs targeting the CRF₁ receptor when treating e.g. depression. Antagonists targeting the CRF₁ receptor to treat e.g. addiction should have fast association and slow dissociation rates to overcome the slow dissociation kinetics of CRF and high plasma concentrations of both CRF and UCNl during stress. Considering that stress-related disorders often need chronic treatment, patients could benefit from slowly dissociating drugs.

Concluding remarks

Drug-target association and dissociation rates play an important role in achieving safe and efficacious drug action *in vivo*. For example, numerous drugs have been proven in retrospect to be highly efficacious due to their slow dissociation rates (Box 3). Currently, drug discovery efforts are moving towards incorporating optimized binding kinetics prospectively. As many successful drugs on the market achieve their effects by competing with endogenous ligands, a better understanding of the pharmacological and physiological behavior of endogenous ligands and their receptors in the human body is crucial. This is particularly important for neuropeptides, since their release is generally pulsatile or in bursts consequent to stress stimuli, ultimately resulting in instant high local concentrations.

Moreover, to understand desired binding kinetics for the target of interest, insights into receptor internalization kinetics are beneficial, as this arguably terminates a drug's effect.

In this review we have presented evidence of varying ligand binding kinetics for the endogenous ligands of three exemplary neuropeptide receptors. In addition to the observed variability in ligand binding kinetics across these three exemplars, receptor internalization kinetics were also largely different for all three discussed neuropeptide receptors. Thus, collectively, this small case overview demonstrates a broad array of kinetic profiles for neuropeptide receptors, i.e. endogenous ligand release rates, binding kinetics and receptor internalization rates. Presently, drug discovery focusses mainly on characterizing drug candidates only, while the kinetic profile of the target receptor and its endogenous ligand(s) are most often neglected. Therefore, we believe it is a great opportunity for future drug research to include the kinetic profile of the target receptor and its endogenous ligand(s) to the drug discovery paradigm. Knowledge of these complete kinetic profiles could improve our understanding of desired binding kinetics and in turn lead to less attrition in (pre-) clinical phases of drug development and to more efficacious drugs.

References

1. Wang, Y., et al., *NeuroPep: a comprehensive resource of neuropeptides*. Database (Oxford), 2015. **2015**: p. bav038.
2. Hoyer, D. and T. Bartfai, *Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach*. Chem Biodivers, 2012. **9**(11): p. 2367-87.
3. Pinter, E., et al., *Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions*. Br J Clin Pharmacol, 2014. **77**(1): p. 5-20.
4. Clynen, E., et al., *Neuropeptides as targets for the development of anticonvulsant drugs*. Mol Neurobiol, 2014. **50**(2): p. 626-46.
5. Griebel, G. and F. Holsboer, *Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?* Nat Rev Drug Discov, 2012. **11**(6): p. 462-78.
6. Kormos, V. and B. Gaszner, *Role of neuropeptides in anxiety, stress, and depression: from animals to humans*. Neuropeptides, 2013. **47**(6): p. 401-19.
7. Arrowsmith, J. and P. Miller, *Trial watch: phase II and phase III attrition rates 2011-2012*. Nat Rev Drug Discov, 2013. **12**(8): p. 569.
8. Swinney, D.C., et al., *The Role of Binding Kinetics in GPCR Drug Discovery*. Curr Top Med Chem, 2015. **15**(24): p. 2504-22.
9. Dahl, G. and T. Akerud, *Pharmacokinetics and the drug-target residence time concept*. Drug Discov Today, 2013. **18**(15-16): p. 697-707.
10. Copeland, R.A., *The drug-target residence time model: a 10-year retrospective*. Nat Rev Drug Discov, 2016. **15**(2): p. 87-95.
11. Guo, D., et al., *Drug-Target Residence Time—A Case for G Protein-Coupled Receptors*. Medicinal Research Reviews, 2014. **34**(4): p. 856-892.
12. Cazzola, M., et al., *Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD*. Pulm Pharmacol Ther, 2015. **31**: p. 68-78.
13. Carboni, L., et al., *Slow dissociation of partial agonists from the D-2 receptor is linked to reduced prolactin release*. International Journal of Neuropsychopharmacology, 2012. **15**(5): p. 645-656.
14. Vauquelin, G., *Impact of target binding kinetics on in vivo drug efficacy: k_{on} , k_{off} and rebinding*. Br J Pharmacol, 2016.
15. Vauquelin, G. and I. Van Liefde, *Slow antagonist dissociation and long-lasting in vivo receptor protection*. Trends Pharmacol Sci, 2006. **27**(7): p. 356-9.
16. Hothersall, J.D., et al., *Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?* Drug Discovery Today, 2015.
17. Hay, D.L. and A.A. Pioszak, *Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles*. Annu Rev Pharmacol Toxicol, 2016. **56**: p. 469-87.
18. Alonso, V. and P.A. Friedman, *Minireview: ubiquitination-regulated G protein-coupled receptor signaling and trafficking*. Mol Endocrinol, 2013. **27**(4): p. 558-72.

19. Guo, D., L.H. Heitman, and I.J. AP, *The Role of Target Binding Kinetics in Drug Discovery*. ChemMedChem, 2015. **10**(11): p. 1793-6.
20. Guo, D., L.H. Heitman, and I.J. AP, *Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors*. Chem Rev, 2016.
21. de Witte, W.E., et al., *Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients*. Expert Opin Drug Discov, 2016. **11**(1): p. 45-63.
22. Lahortiga, I. and L. Cox, *Library of Science and Medical Illustrations. Scientific illustration for the research scientist*. 2015: somersault18:24
23. *Servier medical art. Powperpoint image bank 2015*. Available from: <http://www.servier.com/>.
24. Maggi, R., et al., *GnRH and GnRH receptors in the pathophysiology of the human female reproductive system*. Hum Reprod Update, 2015.
25. Araki, S., et al., *Reevaluation of immunoreactive gonadotropin-releasing hormone (GnRH) levels in general circulation in women: changes in levels and episodic patterns before, during and after gonadotropin surges*. Endocrinol Jpn, 1986. **33**(4): p. 457-68.
26. Finch, A.R., et al., *Trafficking and signalling of gonadotrophin-releasing hormone receptors: an automated imaging approach*. Br J Pharmacol, 2010. **159**(4): p. 751-60.
27. Labrie, F., *GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer*. Endocrine-related cancer, 2014: p. 301-317.
28. Wagner, T.O., T.E. Adams, and T.M. Nett, *GNRH interaction with anterior pituitary. I. Determination of the affinity and number of receptors for GNRH in ovine anterior pituitary*. Biol Reprod, 1979. **20**(2): p. 140-9.
29. Nederpelt, I., et al., *Characterization of 12 GnRH peptide agonists - a kinetic perspective*. Br J Pharmacol, 2016. **173**(1): p. 128-41.
30. Bergquist, F. and M. Ludwig, *Neuropeptide release*, in *Intercellular Communication in the Nervous System*, R. Malenka, Editor. 2009, Academic Press.
31. Anthony, E.L., J.C. King, and E.G. Stopa, *Immunocytochemical localization of LHRH in the median eminence, infundibular stalk, and neurohypophysis. Evidence for multiple sites of releasing hormone secretion in humans and other mammals*. Cell Tissue Res, 1984. **236**(1): p. 5-14.
32. Stopa, E.G., et al., *Computer-assisted mapping of immunoreactive mammalian gonadotropin-releasing hormone in adult human basal forebrain and amygdala*. Endocrinology, 1991. **128**(6): p. 3199-207.
33. Arnold, A.P., et al., *Hormones, brain and behavior*. Vol. 5. 2002, San Diego, California, USA: Academic Press, Elsevier Science.
34. Marshall, J.C. and M.L. Griffin, *The role of changing pulse frequency in the regulation of ovulation*. Hum Reprod, 1993. **8 Suppl 2**: p. 57-61.

35. Herman, A., et al., *Gonadoliberin (GnRH) and its copper complex (Cu-GnRH) enzymatic degradation in hypothalamic and pituitary tissue in vitro*. J Physiol Pharmacol, 2012. **63**(1): p. 69-75.
36. Larco, D.O., et al., *The Novel Actions of the Metabolite GnRH-(1-5) are Mediated by a G Protein-Coupled Receptor*. Front Endocrinol (Lausanne), 2013. **4**: p. 83.
37. Kumar, P. and A. Sharma, *Gonadotropin-releasing hormone analogs: Understanding advantages and limitations*. J Hum Reprod Sci, 2014. **7**(3): p. 170-4.
38. Adrian, T.E., et al., *Neuropeptide Y distribution in human brain*. Nature, 1983. **306**(5943): p. 584-6.
39. Heilig, M., *The NPY system in stress, anxiety and depression*. Neuropeptides, 2004. **38**(4): p. 213-24.
40. Woller, M.J. and E. Terasawa, *Changes in pulsatile release of neuropeptide-Y and luteinizing hormone (LH)-releasing hormone during the progesterone-induced LH surge in rhesus monkeys*. Endocrinology, 1994. **135**(4): p. 1679-86.
41. Abid, K., et al., *Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein*. J Biol Chem, 2009. **284**(37): p. 24715-24.
42. Grouzmann, E., et al., *Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma*. Clin Chem, 2001. **47**(6): p. 1075-82.
43. Swanson, L.W., et al., *Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study*. Neuroendocrinology, 1983. **36**(3): p. 165-86.
44. Hasdemir, B., et al., *Endothelin-converting enzyme-1 actions determine differential trafficking and signaling of corticotropin-releasing factor receptor 1 at high agonist concentrations*. Mol Endocrinol, 2012. **26**(4): p. 681-95.
45. Schulte, H.M., et al., *Corticotropin-releasing factor: pharmacokinetics in man*. J Clin Endocrinol Metab, 1984. **58**(1): p. 192-6.
46. Pawson, A.J., et al., *Mammalian type I gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization*. Endocrinology, 2008. **149**(3): p. 1415-22.
47. Madziva, M.T., et al., *The carboxy-terminal tail or the intracellular loop 3 is required for beta-arrestin-dependent internalization of a mammalian type II GnRH receptor*. Mol Cell Endocrinol, 2015. **411**: p. 187-97.
48. Heding, A., et al., *Gonadotropin-releasing hormone receptors with intracellular carboxyl-terminal tails undergo acute desensitization of total inositol phosphate production and exhibit accelerated internalization kinetics*. J Biol Chem, 1998. **273**(19): p. 11472-7.
49. Behan, D.P., E.A. Linton, and P.J. Lowry, *The Human-Plasma Crf-Binding Protein - Its Isolation Using Affinity-Chromatography*. Journal of Physiology-London, 1988. **399**: p. P90-P90.

50. Ardati, A., et al., *Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay*. Journal of Neuroscience Methods, 1998. **80**(1): p. 99-105.
51. Migaud, M., B.P. Roques, and C. Durieux, *Evidence for a high-affinity uptake system for cholecystokinin octapeptide (CCK8) in rat cortical synaptosomes*. Eur J Neurosci, 1995. **7**(5): p. 1074-9.
52. Nam, S.Y., et al., *Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance*. J Clin Endocrinol Metab, 2001. **86**(10): p. 4849-53.
53. Michel, M.C., et al., *XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors*. Pharmacol Rev, 1998. **50**(1): p. 143-50.
54. Babilon, S., K. Morl, and A.G. Beck-Sickinger, *Towards improved receptor targeting: anterograde transport, internalization and postendocytic trafficking of neuropeptide Y receptors*. Biol Chem, 2013. **394**(8): p. 921-36.
55. Dautzenberg, F.M. and S. Neysari, *Irreversible binding kinetics of neuropeptide Y ligands to Y2 but not to Y1 and Y5 receptors*. Pharmacology, 2005. **75**(1): p. 21-9.
56. Gicquiaux, H., et al., *Rapid internalization and recycling of the human neuropeptide Y Y(1) receptor*. J Biol Chem, 2002. **277**(8): p. 6645-55.
57. Ouedraogo, M., et al., *Distinct motifs of neuropeptide Y receptors differentially regulate trafficking and desensitization*. Traffic, 2008. **9**(3): p. 305-24.
58. Pheng, L.H., et al., *Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells*. Br J Pharmacol, 2003. **139**(4): p. 695-704.
59. Parker, S.L., et al., *Cloned neuropeptide Y (NPY) Y1 and pancreatic polypeptide Y4 receptors expressed in Chinese hamster ovary cells show considerable agonist-driven internalization, in contrast to the NPY Y2 receptor*. Eur J Biochem, 2001. **268**(4): p. 877-86.
60. Walther, C., K. Morl, and A.G. Beck-Sickinger, *Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development*. J Pept Sci, 2011. **17**(4): p. 233-46.
61. Bohme, I., et al., *Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus*. Cell Signal, 2008. **20**(10): p. 1740-9.
62. Parker, S.L., et al., *Ligand internalization by cloned neuropeptide Y Y5 receptors excludes Y2 and Y4 receptor-selective peptides*. Eur J Pharmacol, 2003. **474**(1): p. 31-42.
63. Li, J., Y. Tian, and A. Wu, *Neuropeptide Y receptors: a promising target for cancer imaging and therapy*. Regen Biomater, 2015. **2**(3): p. 215-9.
64. Hallberg, M., *Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors*. Med Res Rev, 2015. **35**(3): p. 464-519.
65. Rizzi, A., et al., *In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant*. Peptides, 2012. **37**(1): p. 86-97.
66. Mould, R., et al., *Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands*. Br J Pharmacol, 2014. **171**(2): p. 351-63.

67. Dautzenberg, F.M., et al., *Corticotropin-releasing factor receptors: CRF1 receptor*. IUPHAR/BPS Guide to PHARMACOLOGY, 2015.
68. Bale, T.L. and W.W. Vale, *CRF and CRF receptors: role in stress responsivity and other behaviors*. Annu Rev Pharmacol Toxicol, 2004. **44**: p. 525-57.
69. Florio, P., et al., *Plasma urocortin levels in the diagnosis of ovarian endometriosis*. Obstet Gynecol, 2007. **110**(3): p. 594-600.
70. Catalan, R., et al., *Plasma corticotropin-releasing factor in depressive disorders*. Biol Psychiatry, 1998. **44**(1): p. 15-20.
71. Goland, R.S., et al., *Plasma corticotropin-releasing factor concentrations in the baboon during pregnancy*. Endocrinology, 1992. **131**(4): p. 1782-6.
72. Bortolato, A., et al., *Structure of Class B GPCRs: new horizons for drug discovery*. Br J Pharmacol, 2014. **171**(13): p. 3132-45.
73. De Souza, E.B., *Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution*. J Neurosci, 1987. **7**(1): p. 88-100.
74. Gottowik, J., et al., *Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin*. Neuropharmacology, 1997. **36**(10): p. 1439-46.
75. Dautzenberg, F.M. and R.L. Hauger, *The CRF peptide family and their receptors: yet more partners discovered*. Trends Pharmacol Sci, 2002. **23**(2): p. 71-7.
76. Bangasser, D.A., et al., *Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology*. Mol Psychiatry, 2010. **15**(9): p. 877, 896-904.
77. Valentino, R.J., E. Van Bockstaele, and D. Bangasser, *Sex-specific cell signaling: the corticotropin-releasing factor receptor model*. Trends Pharmacol Sci, 2013. **34**(8): p. 437-44.